RhumbLine Advisers
IKT icon

RhumbLine Advisers’s Inhibikase Therapeutics IKT Stock Holding History

RhumbLine Advisers’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$244K Buy
120,014
+61,297
+104% +$110K ﹤0.01% 3184
2026
Q1 		$98.6K Buy
58,717
+11,554
+24% +$20.5K ﹤0.01% 3414
2025
Q4 		$96.7K Sell
47,163
-10,388
-18% -$16.5K ﹤0.01% 3485
2025
Q3 		$93.2K Sell
57,551
-973
-2% -$1.69K ﹤0.01% 3542
2025
Q2 		$114K Buy
+58,524
New +$115K ﹤0.01% 3489

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

RhumbLine Advisers's IKT Position: Q2 2026 in Review

RhumbLine Advisers increased its Inhibikase Therapeutics (IKT) stake by 104% in Q2 2026, buying an estimated $110K and bringing the position to 120,014 shares worth $244K. The position accounts for ﹤0.01% of the portfolio, ranked #3184.

RhumbLine Advisers first reported a position in IKT in Q2 2025 and has held it in 5 quarters since. 106 funds tracked by Wall St. Rank hold IKT as of Q2 2026.

  • RhumbLine Advisers held 120,014 shares of Inhibikase Therapeutics worth $244K as of Q2 2026.
  • RhumbLine Advisers bought 61,297 Inhibikase Therapeutics shares in Q2 2026, an estimated $110K.
  • Inhibikase Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #3184 holding.
  • RhumbLine Advisers first reported a position in Inhibikase Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 106 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.